Notably, amiodarone showed equivalent anti-tumor efficacy but with fewer side effects on the treated mice compared to the clinical anti-cancer drug Mitomycin C (MMC). Similarly, low autophagy is associated with a poor overall survival rate. Furthermore, repurposing amiodarone-induced autophagy accompanied by trivial side effects shows potential for the treatment of bladder cancer patients.
TPP exhibited superior neuroprotective efficacy compared with ATP and melatonin, highlighting its potential as a candidate therapeutic agent for amiodarone-related neuropathy. Further clinical research is warranted to support translational application of these findings.